ClinicalTrials.gg
CompletedNCT03926117RESCUEUpdated Dec 31, 2025Results posted

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

A Phase 2 interventional study of Ziltivekimab in Chronic Kidney Diseases and Inflammation, sponsored by Novo Nordisk A/S. Completed at 49 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.

Enrollment
8th of 18
264 · median 128
Started
2019
the only one that year
Phase 2
5 of 29
1 open now
Registered
9th of 29
by date

Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2, and was the 9th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, or all of them as a file.
02

Study summary

Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be 7.5 mg, 15 mg and 30 mg subcutaneous monthly compared to placebo for six months.

03

Conditions studied

  • Chronic Kidney Diseases
  • Inflammation

Keywords

  • IL-6
  • CRP
  • Chronic Kidney Disease
  • Cardiovascular Disease
  • Inflammation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age
  • Stage 3-5 CKD
  • hs-CRP > 2.0 mg/L
  • Comply with

Exclusion criteria

Exclusion Criteria:

  • Low
  • Low count
  • Spot urine protein to creatinine ration > 4000 mg/g
  • /AST >2.5x
  • TSAT \< 10%
  • Positive TB test
  • Evidence of ,
  • Blind or illiterate
  • Expected to require blood transfusion
  • Thromboembolic event within 12-weeks
  • Evidence of active infection
  • Peptic ulcer disease, diverticulitis, inflammatory bowel disease
  • Uncontrolled hypertension
  • Planned coronary revascularization
  • Major cardiac surgery, CHF
  • Active , bone marrow or organ transplant
  • Allergy to study drug
  • Treatment with drug, treatment with HIF stabilizer or ESA
  • Use of drugs, systemic antibiotics
  • Breastfeeding, any other significant medical history
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
264 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo

    Biological: Ziltivekimab

  • Experimental
    Ziltivekimab 7.5 mg

    Biological: Ziltivekimab

  • Experimental
    Ziltivekimab 15 mg

    Biological: Ziltivekimab

  • Experimental
    Ziltivekimab 30 mg

    Biological: Ziltivekimab

Interventions

  • BiologicalZiltivekimab

    human IgG1k anti-human IL-6 monoclonal antibody

    Also known as: COR-001

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels

    Percent change from baseline in hs-CRP levels at week 13 are presented.

    Time frame: Baseline (average of the hs-CRP value prior to randomization and day 1), week 13

Secondary outcomes

  1. Percent Change From Baseline in Serum Amyloid A (SAA)

    Percent change from baseline in SAA at week 13 are presented.

    Time frame: Baseline (average of the values at week -1 and day 1), week 13

  2. Percent Change From Baseline in Fibrinogen

    Percent change from baseline in fibrinogen at week 13 are presented.

    Time frame: Baseline (day 1), week 13

  3. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious AEs (TESAEs), Severe Hematologic AEs, Severe Non-hematologic AEs, and AEs Leading to Drug Discontinuation

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. TEAEs are defined as AEs that initiated or worsened on or after the date of first dose of study drug up to the end of safety-follow-up. A SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. TEAEs that met any of these criteria were considered severe hematologic AEs: grade 3 neutropenia, grade 3 anemia, grade 3 leukopenia, grade 3 lymphopenia, grade 3 eosinophilia, and grade 3 thrombocytopenia.

    Time frame: From week 0 to week 32

  4. Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Events

    Bleeding events were classified using the TIMI bleeding classification as follows: 1) major: intracranial hemorrhage or a \>=5 g/dL decrease in the hemoglobin concentration or a \>=15 percent (%) absolute decrease in the hematocrit; 2) minor: (a) observed blood loss: \>=3 g/dL decrease in the hemoglobin concentration or \>=10% decrease in the hematocrit. (b) no observed blood loss: \>=4 g/dL decrease in the hemoglobin concentration or \>=12% decrease in the hematocrit; 3) minimal: any clinically overt sign of hemorrhage (including imaging) that was associated with a \< 3 g/dL decrease in the hemoglobin concentration or \<9% decrease in the hematocrit.

    Time frame: From week 0 to week 32

  5. Percentage of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESI)

    An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. AESI included serious infections, malignancies, anaphylaxis occurring at any time, even if considered unrelated to the study drug, gastrointestinal perforations, hypersensitivity reaction during investigational product (IP) administration, neutrophils per cubic millimeter (500/mm\^3) (severe) or neutrophils \<1000/mm\^3 (severe) with evidence of concurrent infection, severe injection-related reactions, thrombocytopenia (platelet count \<50,000/mm\^3 (severe)) or platelet count \<75,000/mm\^3 (moderate) with evidence of concurrent TIMI major bleeding.

    Time frame: From week 0 to week 32

  6. Change in Systolic Blood Pressure (SBP)

    Change from baseline in systolic blood pressure at week 32 are presented.

    Time frame: Baseline (week 1), week 32

  7. Change in Diastolic Blood Pressure (DBP)

    Change from baseline in diastolic blood pressure at week 32 are presented.

    Time frame: Baseline (week 1), week 32

  8. Change in Respiratory Rate

    Change from baseline in respiratory rate at week 32 are presented.

    Time frame: Baseline (week 1), week 32

  9. Change in Body Mass Index (BMI)

    Change from baseline in BMI at week 24 are presented.

    Time frame: Baseline (week 1), week 24

  10. Change in Heart Rate

    Change from baseline in heart rate at Week 32 are presented.

    Time frame: Baseline (week 1), week 32

  11. Change in Temperature

    Change from baseline in temperature at week 32 are presented.

    Time frame: Baseline (week 1), week 32

  12. Change in Electrocardiogram (ECG)

    The ECG was assessed by the investigator at baseline (week -1) and week 24 and categorised as abnormal clinically significant, abnormal not clinically significant, indeterminate, normal, not evaluable and unknown. Number of participants in each ECG category at baseline and week 24 are presented.

    Time frame: Baseline (week -1), Week 24

  13. Change in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AAT) Levels

    Change from baseline in ALP, ALT and AAT levels at week 32 are presented.

    Time frame: Baseline (week 1), week 32

  14. Change in Bicarbonate, Chloride, Potassium, Sodium

    Change from baseline in bicarbonate, chloride, potassium, sodium at week 32 are presented.

    Time frame: Baseline (week 1), week 32

  15. Change in Direct Bilirubin, Bilirubin, Calcium, Creatinine, Glucose, Phosphate and Urea Nitrogen

    Change from baseline in direct bilirubin, bilirubin, calcium, creatinine, glucose, phosphate and urea nitrogen at week 32 are presented.

    Time frame: Baseline (week 1), week 32

  16. Follicle Stimulating Hormone (FSH) Levels

    FSH levels at baseline (week -1) are presented.

    Time frame: Baseline (week -1)

  17. Number of Participants With Anti-drug Antibodies (ADAs)

    Participants who had at least 1 positive sample (treatment-boosted or treatment-induced) at any time after their first Ziltivekimab administration were classified as positive for ADAs. In the instance that a participant had a positive sample at the baseline visit, the participant was considered positive only if the peak titer of the post-treatment sample was at least 2-fold higher (i.e., \>=2-fold) than the titer of the baseline sample. Number of participants positive for antibodies to Ziltivekimab are presented.

    Time frame: From week 0 to week 32

07

Results

Posted Aug 9, 2023

Participant flow

The trial was conducted at 52 clinical sites in the United States.

Participant flow — Overall Study
MilestonePlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Started66666666
Intent-to-treat analysis population66666666
Safety analysis population65656665
Treated65656665
Completed60576059
Not completed6967
Withdrew: Unclassified1414
Withdrew: Withdrawal by subject3011
Withdrew: Lost to follow-up0210
Withdrew: Adverse event1231
Withdrew: Randomized but not treated1101

Outcome measures

PrimaryPercent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels

Percent change from baseline in hs-CRP levels at week 13 are presented.

Time frame:
Baseline (average of the hs-CRP value prior to randomization and day 1), week 13
Reported as:
Median · Percent change
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels
Percent changePlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels-4.49 (-35.54 to 46.27)-76.57 (-86.89 to -57.14)-88.12 (-92.11 to -78.95)-91.64 (-95.19 to -86.15)
Statistical analysis
  • Placebo vs Ziltivekimab 7.5 mg · Hodges-Lehmann method · p = <0.0001 · Median difference (final values): -66.20 · 95% CI -86.15 to -49.12
  • Placebo vs Ziltivekimab 15 mg · Hodges-Lehmann method · p = <0.0001 · Median difference (final values): -77.71 · 95% CI -94.98 to -62.97
  • Placebo vs Ziltivekimab 30 mg · Hodges-Lehmann method · p = <0.0001 · Median difference (final values): -87.76 · 95% CI -101.00 to -70.54
SecondaryPercent Change From Baseline in Serum Amyloid A (SAA)

Percent change from baseline in SAA at week 13 are presented.

Time frame:
Baseline (average of the values at week -1 and day 1), week 13
Reported as:
Median · Percent change
Percent Change From Baseline in Serum Amyloid A (SAA)
Percent changePlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Percent Change From Baseline in Serum Amyloid A (SAA)1.82 (-18.42 to 50.98)-40.24 (-61.54 to -12.38)-49.80 (-63.90 to -31.54)-42.45 (-68.91 to -13.48)
SecondaryPercent Change From Baseline in Fibrinogen

Percent change from baseline in fibrinogen at week 13 are presented.

Time frame:
Baseline (day 1), week 13
Reported as:
Median · Percent change
Percent Change From Baseline in Fibrinogen
Percent changePlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Percent Change From Baseline in Fibrinogen-1.62 (-12.90 to 13.35)-25.20 (-33.27 to -7.93)-24.69 (-36.25 to -16.48)-37.17 (-44.94 to -28.57)
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious AEs (TESAEs), Severe Hematologic AEs, Severe Non-hematologic AEs, and AEs Leading to Drug Discontinuation

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. TEAEs are defined as AEs that initiated or worsened on or after the date of first dose of study drug up to the end of safety-follow-up. A SAE was defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. TEAEs that met any of these criteria were considered severe hematologic AEs: grade 3 neutropenia, grade 3 anemia, grade 3 leukopenia, grade 3 lymphopenia, grade 3 eosinophilia, and grade 3 thrombocytopenia.

Time frame:
From week 0 to week 32
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious AEs (TESAEs), Severe Hematologic AEs, Severe Non-hematologic AEs, and AEs Leading to Drug Discontinuation
Percentage of participantsPlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
TEAEs69.266.266.772.3
TESAEs15.420.013.612.3
Severe hematologic AEs1.50.01.50.0
Severe non-hematologic AEs10.818.59.112.3
AEs leading to study drug discontinuation4.66.27.64.6
SecondaryPercentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Events

Bleeding events were classified using the TIMI bleeding classification as follows: 1) major: intracranial hemorrhage or a \>=5 g/dL decrease in the hemoglobin concentration or a \>=15 percent (%) absolute decrease in the hematocrit; 2) minor: (a) observed blood loss: \>=3 g/dL decrease in the hemoglobin concentration or \>=10% decrease in the hematocrit. (b) no observed blood loss: \>=4 g/dL decrease in the hemoglobin concentration or \>=12% decrease in the hematocrit; 3) minimal: any clinically overt sign of hemorrhage (including imaging) that was associated with a \< 3 g/dL decrease in the hemoglobin concentration or \<9% decrease in the hematocrit.

Time frame:
From week 0 to week 32
Reported as:
Number · Percentage of participants
Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Events
Percentage of participantsPlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding Events0.00.00.00.0
SecondaryPercentage of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESI)

An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. AESI included serious infections, malignancies, anaphylaxis occurring at any time, even if considered unrelated to the study drug, gastrointestinal perforations, hypersensitivity reaction during investigational product (IP) administration, neutrophils per cubic millimeter (500/mm\^3) (severe) or neutrophils \<1000/mm\^3 (severe) with evidence of concurrent infection, severe injection-related reactions, thrombocytopenia (platelet count \<50,000/mm\^3 (severe)) or platelet count \<75,000/mm\^3 (moderate) with evidence of concurrent TIMI major bleeding.

Time frame:
From week 0 to week 32
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Treatment-emergent Adverse Events of Special Interest (AESI)
Percentage of participantsPlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Serious infection4.610.84.53.1
Malignancy1.50.01.51.5
Anaphylaxis0.00.00.00.0
Gastrointestinal perforations0.00.00.00.0
Hypersensitivity reaction during IP administration0.00.00.00.0
Neutropenia, severe0.00.00.00.0
Neutropenia, severe with evidence of concurrent infection0.00.00.00.0
Severe injection-related reaction0.00.00.00.0
Thrombocytopenia, moderate with evidence of concurrent TIMI major bleeding0.00.00.00.0
Thrombocytopenia, severe0.00.00.00.0
SecondaryChange in Systolic Blood Pressure (SBP)

Change from baseline in systolic blood pressure at week 32 are presented.

Time frame:
Baseline (week 1), week 32
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Systolic Blood Pressure (SBP)
Millimeters of mercury (mmHg)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Change in Systolic Blood Pressure (SBP)4.8 ± 15.944.9 ± 16.310.6 ± 18.891.2 ± 14.71
SecondaryChange in Diastolic Blood Pressure (DBP)

Change from baseline in diastolic blood pressure at week 32 are presented.

Time frame:
Baseline (week 1), week 32
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure (DBP)
mmHgPlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Change in Diastolic Blood Pressure (DBP)0.7 ± 10.332.9 ± 10.971.1 ± 11.173.1 ± 10.35
SecondaryChange in Respiratory Rate

Change from baseline in respiratory rate at week 32 are presented.

Time frame:
Baseline (week 1), week 32
Reported as:
Mean · Breaths per minute (breaths/min)
Change in Respiratory Rate
Breaths per minute (breaths/min)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Change in Respiratory Rate0.4 ± 2.240.2 ± 2.18-0.7 ± 2.36-0.5 ± 1.62
SecondaryChange in Body Mass Index (BMI)

Change from baseline in BMI at week 24 are presented.

Time frame:
Baseline (week 1), week 24
Reported as:
Mean · Kilograms per square meter (kg/m^2)
Change in Body Mass Index (BMI)
Kilograms per square meter (kg/m^2)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Change in Body Mass Index (BMI)0.13 ± 1.1020.51 ± 1.9040.58 ± 1.6640.40 ± 0.879
SecondaryChange in Heart Rate

Change from baseline in heart rate at Week 32 are presented.

Time frame:
Baseline (week 1), week 32
Reported as:
Mean · Beats per minute (beats/min)
Change in Heart Rate
Beats per minute (beats/min)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Change in Heart Rate2.8 ± 9.701.5 ± 10.18-0.6 ± 8.931.2 ± 11.56
SecondaryChange in Temperature

Change from baseline in temperature at week 32 are presented.

Time frame:
Baseline (week 1), week 32
Reported as:
Mean · Degree Celsius (°C)
Change in Temperature
Degree Celsius (°C)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Change in Temperature0.03 ± 0.456-0.01 ± 0.430-1.13 ± 8.366-0.02 ± 0.615
SecondaryChange in Electrocardiogram (ECG)

The ECG was assessed by the investigator at baseline (week -1) and week 24 and categorised as abnormal clinically significant, abnormal not clinically significant, indeterminate, normal, not evaluable and unknown. Number of participants in each ECG category at baseline and week 24 are presented.

Time frame:
Baseline (week -1), Week 24
Reported as:
Count of participants · Participants
Change in Electrocardiogram (ECG)
ParticipantsPlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Baseline (week-1) — Abnormal, clinically significant0000
Baseline (week-1) — Abnormal, not clinically significant44384046
Baseline (week-1) — Indeterminate0000
Baseline (week-1) — Normal21272518
Baseline (week-1) — Not evaluable0000
Baseline (week-1) — Unknown0000
Week 24 — Abnormal, clinically significant0000
Week 24 — Abnormal, not clinically significant36323534
Week 24 — Indeterminate0000
Week 24 — Normal14221818
Week 24 — Not evaluable0000
Week 24 — Unknown0000
SecondaryChange in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AAT) Levels

Change from baseline in ALP, ALT and AAT levels at week 32 are presented.

Time frame:
Baseline (week 1), week 32
Reported as:
Mean · Units per liter (U/L)
Change in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AAT) Levels
Units per liter (U/L)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
ALP: Change from baseline to Week 32-1.9 ± 14.75-6.3 ± 18.28-9.6 ± 18.56-15.7 ± 13.94
ALT: Change from baseline to Week 321.3 ± 5.532.6 ± 6.565.3 ± 11.767.2 ± 13.73
AAT: Change from baseline to Week 320.6 ± 6.052.3 ± 4.653.3 ± 8.284.8 ± 9.15
SecondaryChange in Bicarbonate, Chloride, Potassium, Sodium

Change from baseline in bicarbonate, chloride, potassium, sodium at week 32 are presented.

Time frame:
Baseline (week 1), week 32
Reported as:
Mean · millimoles per liter (mmol/L)
Change in Bicarbonate, Chloride, Potassium, Sodium
millimoles per liter (mmol/L)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Bicarbonate: Change from baseline to Week 32-0.9 ± 2.60-0.3 ± 2.66-0.7 ± 2.96-1.2 ± 2.72
Chloride: Change from baseline to Week 321.7 ± 3.860.0 ± 3.270.7 ± 2.950.9 ± 3.39
Potassium: Change from baseline to Week 320.00 ± 0.445-0.28 ± 0.739-0.29 ± 0.570-0.16 ± 0.567
Sodium: Change from baseline to Week 321.0 ± 2.920.0 ± 2.700.3 ± 2.44-0.1 ± 2.20
SecondaryChange in Direct Bilirubin, Bilirubin, Calcium, Creatinine, Glucose, Phosphate and Urea Nitrogen

Change from baseline in direct bilirubin, bilirubin, calcium, creatinine, glucose, phosphate and urea nitrogen at week 32 are presented.

Time frame:
Baseline (week 1), week 32
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change in Direct Bilirubin, Bilirubin, Calcium, Creatinine, Glucose, Phosphate and Urea Nitrogen
milligrams per deciliter (mg/dL)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Direct Bilirubin: Change from baseline to Week 32-0.007 ± 0.02970.008 ± 0.02630.018 ± 0.03000.009 ± 0.0367
Bilirubin: Change from baseline to Week 32-0.028 ± 0.12840.060 ± 0.10130.105 ± 0.15760.065 ± 0.1812
Calcium: Change from baseline to Week 32-0.04 ± 0.4940.09 ± 0.4070.16 ± 0.5240.11 ± 0.405
Creatinine: Change from baseline to Week 32-0.041 ± 0.61140.216 ± 0.52910.054 ± 0.34040.141 ± 0.4618
Glucose: Change from baseline to Week 32-15.1 ± 83.488.9 ± 80.509.2 ± 64.861.7 ± 48.43
Phosphate: Change from baseline to Week 32-0.04 ± 0.7780.04 ± 0.7660.02 ± 0.6200.21 ± 0.641
Urea Nitrogen: Change from baseline to Week 320.4 ± 11.764.7 ± 12.151.6 ± 7.975.6 ± 13.89
SecondaryFollicle Stimulating Hormone (FSH) Levels

FSH levels at baseline (week -1) are presented.

Time frame:
Baseline (week -1)
Reported as:
Mean · International units per liter (IU/L)
Follicle Stimulating Hormone (FSH) Levels
International units per liter (IU/L)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Follicle Stimulating Hormone (FSH) Levels57.45 ± 20.49672.70 ± 36.51977.49 ± 33.82758.79 ± 48.167
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs)

Participants who had at least 1 positive sample (treatment-boosted or treatment-induced) at any time after their first Ziltivekimab administration were classified as positive for ADAs. In the instance that a participant had a positive sample at the baseline visit, the participant was considered positive only if the peak titer of the post-treatment sample was at least 2-fold higher (i.e., \>=2-fold) than the titer of the baseline sample. Number of participants positive for antibodies to Ziltivekimab are presented.

Time frame:
From week 0 to week 32
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs)
ParticipantsPlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Number of Participants With Anti-drug Antibodies (ADAs)0457

Adverse events

Collected over From week 0 to week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/65 (1.5%)10/65 (15.4%)19/65 (29.2%)
Ziltivekimab 7.5 mg0/65 (0%)13/65 (20%)22/65 (33.8%)
Ziltivekimab 15 mg0/66 (0%)9/66 (13.6%)18/66 (27.3%)
Ziltivekimab 30 mg0/65 (0%)8/65 (12.3%)17/65 (26.2%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventPlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
Acute kidney injuryRenal and urinary disorders0/652/650/661/65
Corona virus infectionInfections and infestations0/652/650/660/65
Septic shockInfections and infestations0/652/650/661/65
Abdominal painGastrointestinal disorders0/651/650/660/65
Ankle fractureInjury, poisoning and procedural complications0/650/650/661/65
Arteriovenous graft site infectionInfections and infestations0/651/650/660/65
BradycardiaCardiac disorders0/650/650/661/65
Cardiac arrestCardiac disorders1/650/650/660/65
Cardiac failureCardiac disorders1/650/650/660/65
Cardiac failure congestiveCardiac disorders1/650/651/661/65
Most frequent other events
Most frequent other events
EventPlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mg
DiarrhoeaGastrointestinal disorders6/652/651/663/65
HypertensionVascular disorders2/655/656/660/65
CoughRespiratory, thoracic and mediastinal disorders5/651/653/662/65
ArthralgiaMusculoskeletal and connective tissue disorders1/654/652/661/65
HypovolaemiaMetabolism and nutrition disorders2/654/650/660/65
NasopharyngitisInfections and infestations1/654/653/663/65
Oedema peripheralGeneral disorders2/654/651/664/65
Urinary tract infectionInfections and infestations4/654/653/663/65
DizzinessNervous system disorders1/653/654/663/65

Baseline characteristics

Intent-to-treat (ITT) analysis population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mgTotal
Mean65.4 ± 10.8167.2 ± 10.6765.9 ± 9.4267.1 ± 10.5566.4 ± 10.35
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mgTotal
Female29323632129
Male37343034135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mgTotal
Hispanic or Latino2512151971
Not Hispanic or Latino41545146192
Unknown or Not Reported00011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboZiltivekimab 7.5 mgZiltivekimab 15 mgZiltivekimab 30 mgTotal
Race — White50484952199
Race — Black or African American1618121460
Race — Asian00303
Race — Native Hawaiian or other Pacific Islander00101
Race — Other00101
08

Study locations

49 sites
  • Central Alabama Research
    Birmingham, Alabama 35205, United States
  • Aventiv Research
    Mesa, Arizona 85210, United States
  • Arizona Kidney Disease and Hypertension Center
    Phoenix, Arizona 85016, United States
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • North America Research Institute
    Lynwood, California 90262, United States
  • North America Research Institute
    Riverside, California 92503, United States
  • Apex Research of Riverside
    Riverside, California 92505, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • Western Nephrology and Metabolic Bone Disease, PC
    Arvada, Colorado 80002, United States
  • AMPM Research Clinic
    Miami, Florida 33169, United States
  • Ocala Cardiovascular Research
    Ocala, Florida 34474, United States
  • Florida Premier Research Institue, LLC
    Winter Park, Florida 32789, United States
  • Southeastern Clinical Research Institute, LLC
    Augusta, Georgia 30901, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Investigator Research by Design, LLC
    Chicago, Illinois 60643, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Clinical Trials of America, LLC - West Monroe
    Monroe, Louisiana 71201, United States
  • Capital Nephrology
    Greenbelt, Maryland 20770, United States
  • Onyx Clinical Research
    Caro, Michigan 48723, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • St. Clair Nephrology Research
    Roseville, Michigan 48066, United States
  • Nephrology Research of Michigan
    Saint Clair Shores, Michigan 48081, United States
  • DaVita Clinical Research
    Minneapolis, Minnesota 55404, United States
  • Julia and Israel Waldbaum Dialysis Center
    Great Neck, New York 11021, United States
  • Northport VAMC
    Northport, New York 11768, United States
  • DaVita Clinical Research
    The Bronx, New York 10461, United States
  • Mountain Kidney and Hypertension Associates
    Asheville, North Carolina 28801, United States
  • Metrolina Nephrology Associates, PA
    Charlotte, North Carolina 28207, United States
  • Metrolina Nephrology Associates
    Charlotte, North Carolina 28277, United States
  • Southeastern Nephrology - Whiteville
    Whiteville, North Carolina 28472, United States
  • Southeastern Nephrology Associates - Wilmington
    Wilmington, North Carolina 28401, United States
  • Summit Research Group, LLC
    Stow, Ohio 44224, United States
  • Northeast Clinical Research Center
    Allentown, Pennsylvania 18104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Piedmont Research Partners, LLC
    Fort Mill, South Carolina 29707, United States
  • Mountain View CLinical Research - Greer
    Greer, South Carolina 29651, United States
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923, United States
  • Nephrology Associates, PC
    Nashville, Tennessee 37205, United States
  • Renal Disease Research Institute
    Dallas, Texas 75246, United States
  • Vilo Research Group, Inc
    Houston, Texas 77017, United States
  • Biopharma Informatick Inc. Research Center
    Houston, Texas 77043, United States
  • Juno Research, LLC - Northwest
    Houston, Texas 77070, United States
  • North Hills Medical Research, Inc
    North Richland Hills, Texas 76180, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • San Antonio Kidney Disease Center Physicians Group, PLLC
    San Antonio, Texas 78229, United States
  • University of Vermont
    Burlington, Vermont 05401, United States
  • Southside Urology and Nephrology
    Danville, Virginia 25241, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Clinical Investigation Specialist, Inc
    Kenosha, Wisconsin 53142, United States
09

References and documents

Publications

  • Kreiner FF, Kraaijenhof JM, von Herrath M, Hovingh GKK, von Scholten BJ. Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Expert Rev Clin Immunol. 2022 Apr;18(4):377-389. doi: 10.1080/1744666X.2022.2045952. Epub 2022 Mar 1. PubMed 35212585 ↗
  • Hu S, Lee K, He JC, Fan Y. Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2026 Mar 10. doi: 10.2215/CJN.0000001053. Online ahead of print. PubMed 41805697 ↗
  • Aherrahrou R, Reinberger T, Hashmi S, Erdmann J. GWAS breakthroughs: mapping the journey from one locus to 393 significant coronary artery disease associations. Cardiovasc Res. 2024 Nov 5;120(13):1508-1530. doi: 10.1093/cvr/cvae161. PubMed 39073758 ↗
  • Pergola PE, Davidson M, Jensen C, Mohseni Zonoozi AA, Raj DS, Andreas Schytz P, Tuttle KR, Perkovic V. Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE). J Am Soc Nephrol. 2024 Jan 1;35(1):74-84. doi: 10.1681/ASN.0000000000000245. Epub 2023 Dec 13. PubMed 38088558 ↗
  • Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, Libby P, Davidson M; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17. PubMed 34015342 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jun 2020, 12 months.

Results were first posted in Aug 2023, 3 years 1 month after primary completion. A results delay was requested in May 2021.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 12 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2019
First posted
Apr 24, 2019
StartActual
Jun 3, 2019
Primary completionActual
Jun 26, 2020
CompletionActual
Jun 26, 2020
Results delay requested
May 31, 2021
Results first posted
Aug 9, 2023
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03926117
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 24, 2019
Start date
Jun 3, 2019
Primary completion
Jun 26, 2020
Completion
Jun 26, 2020
Results posted
Aug 9, 2023
Last update
Dec 31, 2025

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion